Table 2.

Summary of mTOR inhibitors in combination with other antitumor drugs

mTOR inhibitors	Combined drug	Applied tumor	The effect	References
Everolimus	VEGF inhibitor lenvatinib	RCC	Progression-free survival is significantly extended compared to using them separately	Motzer et al. [75]
PF-384	MEK inhibitor PD-901	HNSCC	They inhibit the production of IL-8 and VEGF and the activation of NF-κB and AP-1	Mohan et al. [76]
AZD8055	HSP90 inhibitor AUY922	Breast cancer	AZD8055 inhibits the upregulation of HSP70 and HSP27 induced by AUY922, while AUY922 blocks the activation of PI3K/Akt induced by AZD805	Chen et al. [78]
Rapamycin	AR inhibitor enzalutamide	HCC	Rapamycin inhibits the AKT/mTOR signaling pathway activated by enzalutamide, while enzalutamide inhibits the up-regulation of AR expression caused by rapamycin	Zhang et al. [77]
Everolimus	Carboplatin and paclitaxel	LCNEC	They improve the overall response rate and disease control rate	Christopoulos et al. [79]
AZD2014	Wee1 inhibitor AZD1775	NSCLC	AZD2014 enhances the effect of AZD1775 by reducing cyclin D1 to enhance DNA damage	Hai et al. [80]

AP-1 activator protein 1, AR androgen receptor, HCC hepatic cell carcinoma, HNSCC head and neck squamous cell carcinoma, HSP90 heat shock protein 90, IL-8 interleukin-8, LCNEC large-cell neuroendocrine carcinoma, MEK MAPK/ERK kinase, NSCLC non-small cell lung cancer, RCC renal cell carcinoma, VEGF vascular growth factor